ReviewInternational journal of nanomedicine2026
Nanotechnology-Enhanced Vaccines for Respiratory Infections: Opportunities and Challenges.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The continued global burden of the respiratory infections, despite availability of effective vaccines against major respiratory pathogens, represents the need to improve vaccination strategies. Although the conventional vaccines have shown effectiveness in many of the infectious diseases, they have serious limitations in developing the mucosal immunity and often fail to provide long-term protection against the rapidly mutating respiratory pathogens. In this area, nanotechnology offers novel solutions to enhance the potential of the respiratory vaccines. This review highlights recent advancements in the diverse nanotechnology platforms for respiratory vaccines, along with their transformative potentials, opportunities as well as challenges by covering the recent trends in the nanotechnology-based respiratory vaccines. Various nanotechnology platforms for respiratory vaccines include lipid nanoparticles (LNPs), polymeric nanoparticles, inorganic nanoparticles, biomimetic and self-assembling nanoplatforms. These platforms potentially address the key limitations of the traditional respiratory vaccines by improving the stability and targeted delivery of antigens, mucosal and cellular immune responses and flexible formulations against the evolving pathogens. However, challenges related to safety, scalability and real world applicability remain. The increasing research endeavors are gradually addressing the longstanding challenges and limitations of the nanotechnological measures in the respiratory vaccination and advancing this field with new opportunities for preventing the respiratory infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.